Get the Stockscreener App
21.07
3.27%
0.61
After Hours:
21.07
Bioage Labs Inc stock is traded at $21.07, with a volume of 305.61K.
It is up +3.27% in the last 24 hours and up +4.86% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$20.46
Open:
$20.71
24h Volume:
305.61K
Relative Volume:
0.46
Market Cap:
$881.19M
Revenue:
$5.92M
Net Income/Loss:
$-75.79M
P/E Ratio:
-9.9664
EPS:
-2.1141
Net Cash Flow:
$-59.15M
1W Performance:
-4.56%
1M Performance:
+4.86%
6M Performance:
+348.62%
1Y Performance:
+372.71%
1-Day Range:
$20.27
$21.35
1-Week Range:
$20.00
$22.59
52-Week Range:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
21.11 | 854.26M | 5.92M | -75.79M | -59.15M | -2.1141 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Upgrade | Jefferies | Hold → Buy |
| Jan-27-26 | Initiated | Piper Sandler | Overweight |
| Dec-05-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Market Trends: How does BioAge Labs Inc perform in inflationary periodsTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit - Law360
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 7,433 shares in 10b5-1 trade - Stock Titan
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (NASDAQ:BIOA) Shares Gap DownHere's Why - MarketBeat
Risk Analysis: How does BioAge Labs Inc perform in inflationary periods2025 Performance Recap & Community Driven Trade Alerts - baoquankhu1.vn
Investment Recap: How do insiders feel about BioAge Labs Inc2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn
BIOA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion - Yahoo Finance
Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of BioAge Labs (BIOA) with Outperform Recommendation - Nasdaq
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal - TipRanks
BioAge Labs (BIOA) Price Target Increased by 10.09% to 30.60 - Nasdaq
Oppenheimer initiates BioAge Labs stock coverage with outperform rating By Investing.com - Investing.com Canada
Oppenheimer initiates BioAge Labs stock coverage with outperform rating - Investing.com
Technical Analysis: Is BioAge Labs Inc backed by strong institutional buyingQuarterly Portfolio Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Fed Watch: Whats the beta of BioAge Labs Inc stock2025 Market Sentiment & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
BioAge Labs, Inc. (BIOA) Receives Buy Rating From Jefferies With Significant Upside Potential - 富途牛牛
BioAge Labs (BIOA) CEO Kristen Fortney awarded 330,000 stock options - Stock Titan
Jefferies upgrades BioAge Labs stock rating on drug potential By Investing.com - Investing.com Nigeria
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Jefferies Upgrades BioAge Labs (BIOA) - Nasdaq
Jefferies upgrades BioAge Labs stock rating on drug potential - Investing.com
Should You Buy BIOAGE Labs Inc (BIOA) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Down 16.3% in January - MarketBeat
Is BioAge Labs Inc.’s ROE strong enough2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - mfd.ru
Will BioAge Labs Inc. stock hit new highs in YEARQuarterly Portfolio Review & AI Forecasted Stock Moves - mfd.ru
Will BioAge Labs Inc. stock deliver long term returnsWatch List & Weekly Breakout Watchlists - mfd.ru
How BioAge Labs Inc. stock benefits from tech adoptionEarnings Trend Report & Real-Time Volume Triggers - mfd.ru
Whale Trades: What is Columbia Sportswear Companys P E ratio telling usJuly 2025 Analyst Calls & Expert-Curated Trade Recommendations - baoquankhu1.vn
Returns Recap: Is BioAge Labs Inc a good stock for dollar cost averagingJuly 2025 Technicals & Consistent Profit Trade Alerts - baoquankhu1.vn
Can BioAge Labs Inc. lead its sector in growthJuly 2025 Weekly Recap & Expert Verified Stock Movement Alerts - mfd.ru
BioAge Labs (NASDAQ:BIOA) Trading Down 5.6%Here's What Happened - MarketBeat
Can BioAge Labs Inc. stock hit analyst price targetsWeekly Trade Analysis & High Accuracy Swing Trade Signals - mfd.ru
S P Trends: Whats the beta of BioAge Labs Inc stockShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
BioAge Labs (BIOA) Price Target Increased by 127.08% to 27.80 - Nasdaq
Morgan Stanley Boosts Price Target on BioAge Labs to $23 From $12, Keeps Equalweight Rating - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Insider Sells $139,368.75 in Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen - MarketBeat
BioAge Labs (NASDAQ:BIOA) Trading 8% HigherHere's Why - MarketBeat
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential - Pharma Voice
BioAge Labs Completes $115 Million Upsized Public Offering - Global Legal Chronicle
Piper Sandler Initiates Coverage of BioAge Labs (BIOA) with Overweight Recommendation - Nasdaq
BioAge Labs (NASDAQ:BIOA) Shares Gap UpShould You Buy? - MarketBeat
Piper Sandler Initiates BioAge Labs at Overweight With $73 Price Target - marketscreener.com
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating - TipRanks
BioAge Labs stock initiated with Overweight rating by Piper Sandler - Investing.com UK
Bioage Labs Inc Stock (BIOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioage Labs Inc Stock (BIOA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Mar 02 '26 |
Sale |
20.30 |
7,433 |
150,890 |
0 |
| GOLDSTEIN DOV A MD | Chief Financial Officer |
Mar 01 '26 |
Option Exercise |
4.38 |
3,542 |
15,514 |
33,033 |
0.18%
1.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):